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ABSTRACT 
Background: Working with patients to be more active participants in their specific interactions with their health 
care providers has been shown to improve the effectiveness of health care consultations for HIV-related 
encounters. This report describes an impact evaluation of a patient education and empowerment training 
program implemented in Namibia for patients on antiretroviral therapy (ART) which was designed to improve 
patient/provider communication and patient clinical outcomes.                                                     
Design and Methods: In order to increase patients’ active engagement during patient-provider interactions, 
we developed and implemented patient training sessions in four ART clinics in Namibia using a “Patient 
Education and Empowerment” training curriculum. We tested the effectiveness of this intervention in a 
randomized controlled trial of 589 patients. At each clinical site, newly initiating ART patients were enrolled, 
with half of those patients randomly assigned to immediately receive three sessions of the training and another 
half to receive the training six months later. The effects of the training on patient engagement during medical 
consultations were measured at each clinic visit for a minimum of eight months of follow up by audiotaping 
and coding the consultation with the provider. Patient-provider communication was measured using a 
validated method for describing medical dialogue, the Roter Interaction Analysis System (RIAS), in addition to 
a global affect scale. RIAS outcomes were compared between intervention and control groups at six months. 
Clinical outcomes associated with the trainings, such as changes in body mass index (BMI) or cluster of 
differentiation four (CD4) count, were compared at six and at 12 months. A mixed effects regression model 
was used in the analysis.   
Results: Two hundred ninety nine newly-initiating ART patients (of whom 195 (65%) were female) were 
enrolled in the intervention group and 290 newly-initiating ART patients (of whom 199 (69%) were female) 
were enrolled in the control group. The average time since HIV diagnosis for each group was 17.1 and 19.7 
months, respectively. At four-to-eight months post enrolment (the window for the six month time point) using 
Intention to Treat (ITT) analysis, consultations in the intervention group had statistically significant higher RIAS 
scores in doctor facilitation and patient activation (adjusted difference in score 1.19, p=0.004, CI=.39,1.99), 
doctor information gathering (adjusted difference in score 2.96, p=0.000, CI=1.42,4.50), patient question asking 
(adjusted difference in score 0.48, p=0.012, CI=.11,.85), and patient positive affect (adjusted difference in score 
2.08, p=.002, CI=(.79,3.36). Doctor affect was also statistically significantly higher in the intervention group 
when measured using the global affect scale (adjusted difference in score 0.60, p=0.02, CI=.08,1.11). No clinical 
outcomes, measured at six and 12 months of follow up, were statistically significant.  
Discussion: Increased engagement of patients in clinical consultation can be achieved via a targeted training 
program integrated into ART clinics so that the trainings complement other services being provided. The 
longitudinal design of this particular study allowed for measurement of communication and clinical changes 
over time. Randomizing the intervention allowed us to better isolate the effects of the training among the 
diverse populations and locations in Namibia. However, loss to follow up at the six month time point when 
outcomes were measured is a limitation. Given the important role of communication in patient adherence and 
to satisfaction with care, RIAS coding methods and other methods designed to measure the quality of patient-
provider interactions should be used more in research in countries with high HIV/AIDS burden.  
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INTRODUCTION  
In Namibia, HIV care and treatment training of health care workers (HCWs) includes an emphasis on “patient 
centeredness”, encouraging HCWs to elicit patient concerns. Through conversations with MoHSS leaders, 
observations of clinicians in ART clinics, routine reporting data and informal conversations with PLWHA leaders, 
it became clear that in spite of HCWs’ best efforts, many patients were minimally engaged in their clinical 
consultation, providing only abbreviated responses to HCW inquiries, initiating few questions, and articulating 
few concerns about their treatment. A range of barriers were theorized to inhibit HIV patient active 
participation in their care, including health literacy, language limitations, normative doctor patient 
expectations, historical contexts, and power differentials. We hypothesized that addressing some of these 
issues through patient education and empowerment trainings would impact the quality of care that HIV 
positive patients receive - both real and perceived - and ultimately improve adherence and clinical outcomes.  
The findings of this study show tangible benefits to both patient and doctor after the trainings, providing 
evidence that education and empowerment actions can immediately and positively influence the quality of 
care provided at the ART clinics.  
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BACKGROUND 
Namibia has made remarkable progress in the rollout of ART services to HIV positive persons in need of 
treatment. The provision of ART in public sector health facilities in Namibia started in 2003 and a subsequent 
rapid scale-up of ART services led to coverage approaching Universal Access targets1.  According to a 2012 
United Nations General Assembly Special Session on HIV/AIDS (UNGASS) report, 67.0% of adults and 75.0% of 
children with advanced HIV infection (meeting World Health Organization (WHO) criteria of CD4 count <= 350 
cells/mm3) in Namibia are receiving ART or a total of 92,000 persons by mid-20112.  Additionally, Namibia’s 
adoption of new WHO ART guidelines, which advocate for starting HIV treatment sooner, has led to increasing 
numbers of individuals eligible for HIV care and treatment. Given the new WHO criteria and new infections, 
the number of people in need of ART is expected to rise to approximately 150,000 in Namibia by 20162. With 
such rapid scale-up of services, the MoHSS is interested in quality of HIV care and understanding the factors 
associated with the effectiveness of HIV treatment support programs.  
It has been shown that patient-provider interactions can impact retention in ART treatment and adherence. 
Three Cochrane reviews lend support for adherence interventions that include improving patient-provider 
interaction.3-5 In the United States, clinical training of HIV health care providers has thus emphasized the 
importance of active listening and patient active participation as key to increasing the quality and effectiveness 
of the patient-provider encounter.6-9 Active listening helps the clinician better hear and understand patient 
physical and psycho-social concerns and complaints and, hence, more effectively respond to them. Active 
listening also involves the skilful use of probing questions to put patients at ease and elicit information that will 
guide clinical advice and treatment. Finally, active listening skills on the part of the provider can encourage 
patient participation and feelings of empowerment in their own care and treatment.6-9 
Despite the number of interventions that involve training physicians, few intervention trials have sought to 
train patients to engage more fully in the health care process.10 The majority of communication studies 
involving patients are designed to assess medical communication largely as a physician monologue with only 
occasional attention to the individual patient’s own  response.11-17,18,19  Few studies focus on the role of the 
patient or patient companion during medical visits, or on ways a patient can be empowered to become more 
engaged in his or her treatment process.20  
This public health evaluation (PHE) sought to determine the effects of patient empowerment training on 
patient active engagement during medical consultations in four different ART clinics in Namibia. A brief 
physician training in active listening was included as part of the overall intervention, to ensure that clinical staff 
had some exposure to the theoretical benefits of patients actively engaging in their clinical consultations. The 
effects of the training on patient engagement during medical consultations were measured using a validated 
method for describing medical dialogue, the Roter Interaction Analysis System (RIAS).18-19 Potential clinical 
outcomes associated with the trainings were also measured in the study, as a secondary research aim.  
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METHODS 
Study Design  
We used a two-armed parallel group randomized, controlled design to evaluate the effectiveness of the patient 
education and empowerment training intervention. Physicians were blinded to the treatment group of the 
patient as much as possible. Newly initiating ART patients at each study site who were eligible and gave 
informed consent were recruited into the study. At each of four ART clinic facilities, consented patients were 
then randomly assigned to the intervention (Group 1) or control (Group 2) group. Data from the two groups 
from each site were aggregated and compared by group to assess the immediate and longer-term effects of 
training patients in active participation in their own clinical care. Comparisons were made between and within 
intervention groups at baseline, six months and 12 months. All health care providers were blinded to the degree 
possible to group assignment. Study coordinators and other staff were not blinded. At six months, differences 
in patient engagement with their health care providers, between intervention and control groups were 
analysed and at 12 months differences in health outcomes were analysed. A total of 589 participants were 
enrolled into the study out of the 592 enrolment target (Figure 1).  
The four ART clinics were purposively selected in association with the MoHSS as study sites in order not to 
conflict with or confound on-going research being conducted by other entities. Every effort was made to 
choose comparable sites in terms of number of patients on ART, number of doctors and nurses, and number 
of newly initiating ART patients each month.  At the same time, facilities from different regions were selected 
to better understand the variability of intervention implementation and results. Katima Mulilo (Caprivi Region), 
Rundu (Kavango Region), Onandjokwe (Oshikoto Region), and Katutura Health Centre (Khomas Region) were 
the selected sites. These facilities had patients with similar characteristics, comparable infrastructures, routine 
collection of the proposed outcome measures, systems that can support studies conducted at the facility, and 
are easily accessed. Each site was asked to enrol 148 participants; 74 in the intervention group and 74 in the 
control group. 
 
 
 
 
 
 
 
 
 
 
 
 
4 ART Clinic  
Study Sites 
Randomization 
X3 X2 X1
1 
Enrolment 
(and baseline  
data collection)  
Intervention 
(X1, X2, X3) 
Empowerment 
Trainings 
O 
  3 months   6 months   9 months 15 months   12 months 
X3 X2 X1 
Termination of study and 
measurement of clinical 
outcomes  
Controls (N=296) 
Measurement of 
patient engagement 
outcomes 
Intervention (N=296) 
Figure 1: Study Randomization, Intervention and Follow Up 
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Study Sites and Personnel 
Training of four study coordinators occurred in November and early December of 2011. Study sites were 
opened in December of 2011 and were actively recruiting study patients and collecting data until July 2013. 
Other activities at the sites during January-March of 2012 included 1) training of trainers in the Patient 
Education and Empowerment Curriculum, 2) training of health care personnel in active listening and 3) a 
routine site monitoring visit in March of 2012. Each site subsequently hired research assistants so that each 
site included a site coordinator, trainer and research assistant. Sites were monitored every quarter starting in 
March 2012.  
Data Collection Methods 
Recruitment and Enrolment of Patients: 
Study coordinators approached patients in the waiting room at the ART clinics. Each clinic has dedicated days 
of the week for newly initiating ART patients. Coordinators screened the patient for interest in participation, 
age (≥18 years old), treatment status (newly initiating ART), planned main point of care (including verifying 
their residence was within a reasonable distance from the facility), and time availability to answer questions 
and complete the three trainings. If the above criteria were met, the coordinator assigned a screening ID to the 
patient and then proceeded to start the informed consent process. A standard set of locator information was 
collected at time of enrolment and updated at each visit. 
Recruitment and enrolment activities continued in this manner until the desired sample sizes for patients in 
each arm of the study had been achieved. Some sites over- or under-enrolled depending on the success of 
recruitment. An in-depth log was kept on the number of patients approached, number of patients screened, 
number of patients enrolled and those screened that did not enrol.  
Randomization: 
Once enrolment data were collected, the patient was randomized to Group 1 or 2 and given a unique study ID 
number. Envelopes with the study ID number, and randomly allocated group assignment, were opened only at 
the time of randomization of each new enrolled patient. Group assignment was noted in the patient enrolment 
log held by the study coordinator. Patients were asked to not disclose information about the intervention to 
other ART patients. Group 1 was the intervention group. Group 2 was the control group who received the 
intervention 6 months after Group 1.  
Outcome Measurement:  
Once enrolled in the study, outcome measures were collected at each clinic visit from both patients and 
providers for the duration of the study. Clinical outcomes were collected for each enrolled patient through 
abstraction of patient charts at the hospital (Table 1).  
To measure the impact of the intervention on patient-provider interactions, we used RIAS, an evidence-based 
communication, education, research and practice tool18-19. The method has been tested for validity and 
reliability many times over in various clinical situations and has shown great coding adaptability to various types 
of interaction, low resource international settings, cultural groups and disease specific interventions21-22. RIAS 
was used to measure the amount of patient engagement with their health care provider, the main outcome 
for the study. Each follow-up clinic visit for all patients enrolled in the study was audio-taped and coded using 
RIAS coding methodologies and RIAS software. If any interpreters were present during the consultation this 
dialogue was also coded. In addition to RIAS medical codes, additional codes were developed and logged in 
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coding books based on local context and language use. Study coordinators at each site were trained extensively 
to listen to the medical dialogue in each recorded consultation and code appropriately. Periodic reliability 
studies were performed, using English language audio-files, to determine inter-coder reliability. Weekly coding 
calls were organized to support the coding work at the study sites and to reach consensus on how different 
utterances, from either the patient or the physician, should be coded. When decisions were made about how 
to code utterances, these coding norms were added to the coding logbooks. Some additional process 
monitoring of the trainings was conducted for quality assurance.  
In addition to RIAS coding, study coordinators assessed each clinical consultation for global affect using a 
standardized scale that indicates subjective measures of overall doctor and patient affect during the 
consultation. Examples of global affect that are coded are physician dominance, patient and physician 
interactivity, patient and doctor anger and upset and patient and doctor empathy and friendliness. Global 
affect scales have been developed and validated in many studies and settings by the same study team that 
developed RIAS.  
Other outcomes include patient satisfaction with the care they have received from their providers, and the 
provider’s perspective on the patient’s level of engagement. To measure these outcomes, health care providers 
were asked to complete a brief one-page consultation assessment form after each consultation with a 
participant enrolled in the study. The consultation assessment form was brief to ensure that clinicians were 
able to complete it immediately after each interaction with an enrolled participant for the duration of the 
study. The questions asked about provider perceptions of participant involvement during the consultation. 
Participants enrolled in the study were also asked to complete a brief consultation assessment form after each 
clinical consultation. This survey included some open-ended questions designed to elicit more in-depth 
participant perspectives on the clinical consultations and was designed to measure, among other outcomes, 
participant capacity to manage their HIV disease.  
 
As noted, to measure clinical outcomes, data was extracted from study participant medical charts at baseline, 
and then on a quarterly basis for the duration of the study to document adherence to care and treatment and 
health outcomes. The following data points were extracted: WHO clinical stage at initiation of ART (and any 
further staging that occurs); fulfilled and missed consultation appointments; fulfilled and missed pill pick-up; 
CD4 count; BMI (calculated); treatment regimen; and recorded diagnosed opportunistic infections (OIs) 
(tuberculosis (TB), sexually transmitted infections (STIs), etc.) and referrals for OIs. 
Data Collection Summary 
Table 1: Summary of Study Data Collected 
Site # Enrolled  Enrolment 
Forms 
Total RIAS 
Recordings  
Total Patient 
Exit Interviews 
Total Provider 
Exit 
Interviews 
Mean # Clinic 
Visits 
Abstracted 
Windhoek 199 (100 I*/99 
C) 
199 718 666 834 12 Clinic Visits 
Rundu 169 (86 I/83 C) 169 579 386 424 6 Clinic Visits 
Onandjokwe 115 (55 I/50 C) 115 354 445 529 6 Clinic Visits 
Katima  106 (58 I/58 C)  106 195 294 284 6 Clinic Visits 
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*I=Intervention, C=Control  
 Data Analysis 
Data related to patient demographics were gathered from patients in both groups at enrolment and compared 
between the trained Group 1 and the untrained Group 2. The coded audio-tapes in RIAS were quantified and 
frequencies and overall composite scores for all categories calculated. Global affect scores for both doctor and 
patient were analysed.  
RIAS and global affect outcomes were compared at six months (using a four-eight month window) between 
Groups 1 and 2 to test the post-intervention quality of patient/provider interactions (e.g., frequency of provider 
initiated utterances, frequency of participant initiated utterances, and length of consultation). A mixed effects 
model was used for the regression, with adjustment for site, length of consultation, nurse vs. doctor, provider, 
provider sex, patient gender, and whether an interpreter was present. To examine longer term impact of the 
intervention on health outcomes, clinical outcomes were compared between Groups 1 and 2 at twelve-months. 
We applied an intention-to-treat approach in this analysis, considering all available observations provided by 
participants.  
Tables were produced showing means, proportions and results of statistical tests between groups at each time 
point.  Unadjusted comparisons at a given time point were performed with a simple t-test.  Adjusted 
comparisons were made using standard linear regression, adjusting for potential confounders.  
Since ART clinic visits occur approximately quarterly, windows around six months and 12 months were defined 
to specify which observations in follow-up contributed to the six-month and 12-month analyses.  For “six-
month” analyses, we used measurements taken between four and eight months.  For “12-month” analyses, we 
used all observations available at 12 months and later. These time windows resulted in more than one 
observation per person identified for analysis at a given time point.  Nevertheless, we used all the observations 
in the analysis by using linear mixed model methodology in the linear regression, with random effects to 
account for correlation in repeated measures on the same person.  A random effect for clinician (using a 
provider ID) was also included to adjust for correlation in measures taken from participants seeing the same 
clinician. 
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FINDINGS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
887 Screened 
594 Randomized 
238 Not eligible 
55 Eligible but not enrolled 
293 Randomized 
to Control 
301 Randomized 
to Intervention 
208 completed Training 1, 2 and 3 (71.7%) 
7 completed Training 1 and 2 (2.4%) 
7 completed Training 1 only (2.4%) 
68 were not trained (23.5%)  
 
  3 Not eligible 
290 Followed Up 
  2 Not eligible 
299 Followed Up 
129 (180 Observations) Available at 
6 Months for 1° Outcome Analysis 
(RIAS/Global Affect)  
52 (116 Observations) Available at 
12+ months for 2° Outcome 
Analysis (Clinical)  
Total Lost to Follow Up: 27 (9%) 
Reasons for Loss to Follow Up: 
Transferred to New Clinic (13), Did 
not Return (7), Withdrew (1), Death 
(4), ART Treatment Stopped (2) 
 
160 (213 Observations) Available at 
6 Months for 1° Outcome Analysis 
(RIAS/Global Affect)  
63 (83 Observations) Available at 
12+ months for 2° Outcome 
Analysis (Clinical)  
Total Lost to Follow Up: 42 (14%) 
Reasons for Loss to Follow Up: 
Transferred to New Clinic (15), Did 
not Return (14), Withdrew (5), 
Death (5), Treatment Stopped (3) 
 
 
 
228 completed Training 1, 2 and 3 (76.2%) 
23 completed Training 1 and 2 (7.8%) 
12 completed Training 1 only (4.0%) 
36 were not trained (12.0%)  
 
Intervention Fidelity 
Figure 2: PHE Namibia Study Cascade 
 9 |  
Baseline 
 
The demographic characteristics of the study population varied considerably by site (Table 2). Most participants 
in the study were female (67.0%) and this was especially high at the Rundu site (78.0% female). Employment 
was highest in Windhoek, at Katutura Health Centre, with 53.0% of the participants stating that they were 
currently employed. Katima participants reported the highest educational levels, with 79.0% having gone to 
Secondary school compared to 66.0% overall in the study. Marital status  
Table 2: Baseline Characteristics of Study Population by Study Site 
Participant Characteristic Katutura 
Health 
Centre 
Rundu 
 
Katima 
 
Onandjokwe 
 
Total 
 
N enrolled 199 169 115 106 589 
Demographics  
Female gender 116 (58%) 132 (78%)* 77 (67%) 69 (65%) 394 (67%) 
Age        – mean (SD)  35 (8.5) 32 (6.7)** 34 (8.5) 35 (8.6) 34 (8.0) 
               – median (IQR) 34 (29-40) 31 (27-36) 34 (28-40) 34 (29-41) 33 (28-39) 
Employed 106 (53%) 53 (31%)* 11 (10%)* 40 (38%)* 210 (36%) 
Education       
   None 15 (8%) 7 (4%) 1 (1%)* 7 (7%) 30 (5%) 
   Primary 59 (30%) 47 (28%) 23 (20%) 34 (32%) 163 (28%) 
   Secondary 118 (59%) 112 (66%) 91 (79%)* 65 (61%) 386 (66%) 
   Post-Secondary 7 (4%) 3 (2%) 0 (0%)* 0 (0%)* 10 (2%) 
Marital Status      
  Single 114 (57%) 82 (49%) 45 (39%)* 68 (65%) 309 (53%) 
  Married 34 (17%) 16 (9%)* 55 (48%)* 13 (12%) 118 (20%) 
  Separated or Divorced 1 (.5%) 2 (1%) 7 (6%)* 6 (6%)* 16 (3%) 
  Widowed 1 (.5%) 7 (4%)* 7 (6%)* 4 (4%)* 19 (3%) 
  Live with Partner (Unmarried) 49 (25%) 62 (37%)* 1 (1%)* 14 (13%)* 126 (21%) 
*Pearson’s chi square (1df), p <0.05 w/ Katutura as reference site  
** t-test for difference in means, p <0.05 w/ Katutura as reference site 
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varied considerably between sites, with only 9.0% of participants reporting a ‘Married’ marital status at Rundu 
site compared to 12.0% at Onandjokwe site, 17.0% at Katutura Health Centre and 48.0% at Katima Mulilo.  The 
number of women reporting pregnancy at baseline was highest at Rundu site (26.0%), lowest at Katima site 
(4.0%) and 16.0% overall for the study. Considering health status at baseline, study patients overall seemed to 
be most unhealthy at the Onandjokwe site, with a longer time period living with HIV before treatment (mean 
of 24 months), a lower mean BMI than any other site (19.7) and the lowest overall mean weight (56.4 kilos). 
Participant Characteristic Katutura 
Health 
Centre 
Rundu 
 
Katima 
 
Onandjokwe 
 
Total 
 
Reproductive characteristics  
Using family planning method 
(women) 
41 (36%) 68 (51%)* 43 (56%)* 28 (41%) 180 (46%) 
Pregnant (women)       
          Yes 18 (16%) 34 (26%)* 3(4%)* 8 (12%) 63 (16%) 
          Don’t know 1 (1%) 6 (5%)* 0 (0%) 2 (3%) 9 (2%) 
Live births (women)  Mean (SD) 2.0 (1.4) 1.8 (1.3) 1.8 (1.6) 2.8 (2.4)** 2.0 (1.6) 
                                      Median (IQR) 2.0 (1-3) 2.0 (1-2) 2.0 (1-3) 2.0 (1-3.5) 2.0 (1-3) 
Children (men)     Mean (SD) 3.2 (2.2) 3.2 (2.1) 2.4 (1.5) 3 (2.3) 3 (2.1) 
                                Median (IQR) 3.0 (1-4) 2.0 (2-4) 2.0 (1-3) 2.0 (1-4) 2 (2-4) 
HIV characteristics 
Months since first positive HIV test: 
             
             -- Mean (SD) 
 
 
14.7 (19.6) 
 
 
19.7 (26.1)**  
 
 
16.9 (24.3) 
 
 
24.4 (24.5)** 
 
 
18.4 (23.7) 
             -- Median (IQR) 5.7 (1.2-23.3) 4.4 (1.4-31.3)  3.6 (1.0-
25.0) 
14.8 (2.9-44.2) 5.7 (1.4-30.4) 
Unknown or missing 19 (9.6%) 6 (3.6%)  7 (6.1%)  3 (2.8%)  35 (5.9%) 
Body Mass Index (BMI)      
             -- Mean (SD) 22.3 (3.5) 22.5 (4.0) 21.5 (3.7) 19.7 (3.6) 21.7 (3.8) 
             -- Median (IQR) 22.3 (19.8-
24.3)  
22.2 (19.7-
24.3) 
20.7 (18.5-
23.9) 
19.2 (17.3-21.5)  21.3 (18.9-
23.9) 
Unknown or missing 61 (30.7%) 23 (13.6%) 41 (35.7%) 18 (17.0%) 143 (24.3%) 
Weight (kg)      
-- Mean (SD) 59.9 (10.5) 60.6 (11.9) 58.7 (9.8) 56.4 (10.3) 59.2 (10.9) 
                -- Median (IQR) 
 
 
Unknown or missing  
59.0 (54.0-
64.5) 
 
23 (11.6%) 
60.0 (52.9-
68.0) 
 
6 (3.6%) 
58.0 (52.0-
64.0) 
 
14 (12.2%) 
56.0 (49.0-60.0)  
 
 
1 (.9%)  
58.6 (52.0-
65.0)  
 
44 (7.5%) 
WHO clinical stage at ART initiation      
  Stage 1 141 (78%) 17 (10%)* 55 (50%)* 89 (87%)* 302 (54%) 
  Stage 2 14 (8%) 119 (72%)* 26 (24%)* 10 (10%) 169 (30%) 
  Stage 3 22 (12%) 26 (16%) 28 (26%)* 2 (2%)* 78 (14%) 
  Stage 4 
 
Unknown or missing 
3 (2%)  
 
19 (9.5%) 
3 (2%) 
 
4 (2.4%)*  
0 (0%) 
 
6 (5.2%) 
1 (1%) 
 
4 (3.8%)   
7 (1%)  
 
33 (5.6%) 
*Pearson’s chi square (1df), p <0.05 w/ Katutura as reference site  
** t-test for difference in means, p <0.05 w/ Katutura as reference site 
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The WHO clinical stage reported for each site varies considerably and it is probably that use of staging criteria 
is not uniform across the four sites in the study (Table 2). The baseline characteristics by study arm were not 
statistically significantly different, with the exception of the proportion of patients in the intervention group 
versus the control group who were considered WHO Stage 2 (25% versus 36% respectively, p=0.005) at baseline 
(Table 3). It is not clear why this characteristic is different between groups.  
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Participant Characteristic  Intervention Control  
Demographics  N=299 N=290 
Female gender 195 (65%) 199 (69%) 
Age        – Mean (SD)  34 (8.1) 34 (8.2) 
               – Median (IQR) 33 (29-39) 33 (28-39) 
Employed 110 (37%)  102 (35%) 
Education    
   None 16 (5%) 14 (5%) 
   Primary 83 (28%) 81 (28%) 
   Secondary 196 (66%) 190 (65%) 
   Post-Secondary 4 (1%) 6 (2%) 
Marital Status   
  Single 155 (52%) 153 (53%) 
  Married 67 (22%) 53 (18%)  
  Separated or Divorced 7 (2%) 9 (3%) 
  Widowed 10 (3%) 9 (3%) 
  Live with Partner (Unmarried) 60 (20%) 66 (23%)  
Reproductive characteristics   
Using family planning method 
(women) 
93 (48%) 87 (44%) 
Pregnant (women)    
          Yes 28 (14%)  36 (18%) 
          Don’t know 6 (3%)  4 (2%)  
Live births (women)   
               -Mean (SD) 
 
2.11 (1.72) 
 
2.04 (1.63) 
               -Median (IQR) 2.0 (1-3) 2.0 (1-3) 
Children (men)  
-Mean (SD) 
 
3.09 (2.15)  
 
2.93 (2.08) 
-Median (IQR) 3.0 (1-4)  2.0 (2-4) 
HIV characteristics   
Months since first positive HIV 
test: 
             -- Mean (SD) 
 
 
17.1 (22.9)  
 
 
19.7 (24.4) 
             -- Median (IQR) 5.1 (1.3-26.8)  6.9 (1.5-33.1) 
   Unknown or missing 18 (6.0%)  16 (5.5%) 
Body Mass Index (BMI)   
             -- Mean (SD) 21.7 (3.7) 21.8 (4.0)  
            -- Median (IQR) 21.2 (19.1-23.9)  21.5 (18.8-23.9)  
  Unknown or missing  65 (21.7%) 77 (26.6%) 
Weight (kg)   
-- Mean (SD) 59.2 (10.6)  59.2 (11.2)  
              -- Median (IQR) 
 Unknown or missing  
58.0 (52.1-64.0) 
19 (6.4%) 
59.0 (52.0-65.0)  
24 (8.3%) 
 
 
Participant Characteristic  Intervention 
 
Control  
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WHO clinical stage at ART 
initiation 
  
  Stage 1 161 (57%)  141 (51%)  
  Stage 2 71 (25%) 98 (36%)* 
  Stage 3 45 (16%)  33 (12%)  
  Stage 4 
 
Unknown or missing  
3 (1%)  
 
19 (6.4%) 
4 (1%)  
 
13 (4.5%) 
*Pearson’s chi square (1df), p=0.005 
 
 
 
 
 Six Months Post-Intervention   
For all sites combined and for both study arms RIAS and global affect outcomes were analysed at the six month 
follow up time point. For the purposes of the study these were any clinical consultations from four months of 
follow up (and thus occurring after the training intervention) up to eight months of follow up. For RIAS 
outcomes a total of 393 consultations were analysed for this time period from a total of 289 participants (Table 
4). For global affect outcomes a total of 381 consultations were analysed for this time period from a total of 
286 participants. A mixed effects regression model was used to compare the two groups, first unadjusted and 
then adjusted for site, length of consultation, nurse versus doctor, provider, provider sex, patient gender, and 
whether an interpreter was present. For the RIAS outcomes measured (using intention to treat (ITT) analysis) 
four outcomes were statistically significant at the six month time point, indicating a statistically significant 
higher mean in the trained group. Consultations in the intervention group had statistically significant higher 
RIAS scores in doctor facilitation and patient activation (adjusted difference in score 1.19, p=0.004, 95% 
CI=.39,1.99), doctor information gathering (adjusted difference in score 2.96, p=0.000, 95% CI=1.42,4.50), 
patient question asking (adjusted difference in score 0.48, p=0.012, 95% CI=.11,.85), and patient positive affect 
(adjusted difference in score 2.08, p=0.002, 95% CI=(.79,3.36). Doctor positive affect was also statistically 
significantly higher in the intervention group when measured using the global affect scale (adjusted difference 
in score 0.60, p=0.02, 95% CI=.08,1.11) (Table 4).  
 
        Table 4: 6 Month RIAS and Global Affect Measures by Study Arm 
Baseline patient –provider 
interaction measure 
Group 1, 
Intervention 
Mean (SD) 
Group 2, 
Control 
Mean (SD) 
Difference in 
score 
(95% CI) 
P-value Adjusted 
Difference 
(95% CI) 
Adjusted  
P-value 
Doctor RIAS variables        
N observations 213 180  
N participants  160 129 
Physician verbal dominance    0.54 (0.12) 0.55 (0.13) 0.002 
(-0.02, 0.02) 
0.85 
.007 
(-0.01, 0.03)  
0.54 
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Baseline patient –provider 
interaction measure 
Group 1, 
Intervention 
Mean (SD) 
Group 2, 
Control 
Mean (SD) 
Difference in 
score 
(95% CI) 
P-value Adjusted 
Difference 
(95% CI) 
Adjusted  
P-value 
Facilitation and patient 
activation   
5.64 (5.20) 4.59 (3.86) 1.10 
(0.28, 1.92) 
0.01 
1.19 
(0.39, 1.99) 
0.004 
Doctor positive affect   
 
4.21 (4.92) 3.50 (3.55) 0.66  
(-0.14, 1.45) 
0.11 
0.74 
(-0.04, 1.52) 
0.06 
Patient-centeredness  
 
1.18 (1.00) 1.00 (0.99) 0.12  
(-.06, .31) 
0.18 
0.14 
(-0.05, 0.33) 
0.14 
Doctor information gathering   9.52 (9.62) 7.00 (7.28) 2.81  
(1.23, 4.39) 
0.000 
2.96 
(1.42, 4.50) 
0.000 
Patient RIAS Variables        
All patient question asking  2.10 (1.53) 1.05 (1.44) 0.51 
(0.12, 0.89) 
0.01 
0.48 
(0.11, 0.85)  
0.012 
Patient activation and 
engagement  
0.91 (1.38) 0.98 (1.36) 0.02 
(-0.26, 0.30) 
0.90 
0.03 
(-0.25, 0.32) 
0.81 
Patient positive affect  8.94 (8.77) 6.68 (6.40) 2.11 
(.80, 3.42) 
0.002 
2.08 
(0.79, 3.36)  
0.002 
Global Affect        
N observations 207 174  
N participants  159 127 
Doctor Global Affect        
Positive affect 10.73 (2.76) 10.21 (2.76) .60  
(.08, 1.12) 
0.024 
0.60 
(0.08, 1.11)  
0.02 
Dominance/Assertiveness 3.36 (.74) 3.30 (.73) .07  
(-.05, .18) 
0.25 
0.07  
(-0.04, 0.18) 
0.22 
Interactivity  3.67 (.77) 3.57 (.73) .13 
(-.01, .27) 
0.07 
0.13 
(-0.005, 0.26)  
0.06 
Patient Global Affect        
Positive affect  14.75(3.05) 14.37 (2.84) .34  
(-.17, .85) 
0.19 
0.33 
(-0.16, 0.83)  
0.19 
Interactivity  3.34 (.87) 3.28 (.79)  .09 
(-.06, .24 
0.23 
0.09 
(-0.05, 0.23)  
0.22 
 
No other global affect outcomes were statistically significantly different between the two study groups, 
although a few are close to significance at p=0.06 (doctor interactivity as measured by the global affect scale 
and doctor positive affect as measured by RIAS). Still, the majority of non-significant patient-provider 
interaction outcome means are higher in the intervention group. This indicates that perhaps with a larger 
sample size more of the outcomes would be statistically significant.  
 
As part of the analysis the RIAS and global affect outcomes were also modelled with all observations included 
from baseline to eight months of follow up. The results of these analyses are depicted in Table 5 and in Figures 
3-7. When all observations up to eight months are included, three of the thirteen outcome variables remain 
statistically significant, indicating statistically significant differences (for these three outcomes) between the 
two study groups over time and not just in the four-eight month window. The statistically significant outcomes 
are the RIAS outcome for doctors: facilitation and patient activation (difference .58, 95% CI=.05, 1.12, p=0.03) 
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as well as the RIAS patient outcomes:  all patient question asking (difference .27, 95% CI=.05,.49, p=0.01) and 
patient positive affect (difference 1.11, 95% CI=.22,2.00, p=0.01) (Table 5). None of the global affect outcomes 
remained statistically significant when all observations were used. In these analyses none of the slopes for 
intervention and control arms were statistically significantly different from each other, although several slopes 
were statistically significantly negative over the time period of the study (Table 5). The exception was patient 
centeredness, with a positive slope of .04 over time which was statistically significant (p=0.000). 
 
    Table 5: RIAS and Global Affect Outcomes for All Observations from 0-8 Months, by Study Arm 
 
In graphing all five outcomes that were statistically significant at the six month window, it appears that these 
measures of patient-provider interactions were relatively high at the start of the study, even higher at one 
month and then decline over time until the time that the control group is trained at six months (Figures 3-7). 
These measurements are consistent with the clinic visits of patients initiating ART, with longer and more 
complex consultations with the provider at two weeks and again at six weeks and shorter and less complex 
consultations as time goes on. Overall for ART visits, then, the quality of interactions between patient and 
Baseline patient –
provider interaction 
measure 
Intervention 
Slope  
(95% CI) 
 
 
Control  
Slope  
(95% CI) 
 
 
Overall slope 
(95% CI) 
 
 
P-
value 
 
Overall difference 
between arms 
(95% CI) 
 
 
P-
value 
Doctor RIAS variables        
Physician verbal 
dominance 
-.005   
(-.012, .002)  
-.005  
(-.007, -.002) 
-.005  
(-.007, -.003) 
0.000 -.006 (-.02, .005) 0.25 
Facilitation and patient 
activation 
-.26 (-.59, .07) -.30 (-.45, -.16)  -.28 (-.38, -.12)  0.000 .58 (.05, 1.12)  0.03 
Doctor positive affect  .12 (-.16, .41) .03 (-.10, .15) .08 (-.01, .17) 0.08 .21 (-.25, .68) 0.37 
Patient-centeredness  .05 (-.02, .11) .04 (.01, .07) .04 (.02, .06) 0.000 .06 (-.03, .16) 0.20 
Doctor information 
gathering  
-.10 (-.78, .58) -.37 (-.67, -.07)  -.22 (-.43, -.01)  0.04 1.02 (-.09, 2.12) 0.07 
Patient RIAS Variables        
All patient question 
asking  
.04 (-.09, .17) .03 (-.02, .09) .04 (-.003, .08) 0.07 .27 (.05, .49)  0.01 
Patient activation and 
engagement  
-.03 (-.13, .07) -.04 (-.09, .002) -.04 (-.07, -.005)  0.02 .09 (-.07, .25) 0.28 
Patient positive affect  -.09 (-.69, .51)  -.28 (-.54, -.02) -.18 (-.36, .007) 0.06 1.11 (.22, 2.00) 0.01 
Global Affect        
Doctor Global Affect        
Positive affect -.21 (-.42, -.004)  -.26 (-.35, -.16) -.23 (-.30, -.17) 0.00 .25 (-.06, .55)  0.12 
Dominance/Assertiveness -.01 (-.06, .04) -.002 (-.02, .02) -.007 (-.02, 
.007) 
0.32 .04 (-.02, .11) 0.21 
Interactivity  -.02 (-.07, .03) -.02 (-.04, .002)  -.02 (-.04, -.005) 0.01 .04 (-.04, .13) 0.30 
Patient Global Affect        
Positive affect -.11 (-.32, .09) -.08 (-.16, .01) -.10 (-.16, -.04) 0.002 .32 (-.03, .67) 0.07 
Interactivity  -.03 (-.09, .03) -.04 (-.06, -.01) -.04 (-.05, -.02) 0.000 .06 (-.04, .15) 0.25 
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provider mostly declines each month after ART initiation, regardless of which group a study patient is in (and 
in fact there are several statistically significant negative slopes shown in Table 5). Still, the effect of the training 
is clearly shown in these graphs, with the intervention group showing higher scores early in the study and 
throughout the study until approximately seven-eight months of follow up. The effect of training the control 
group is also clear, with a rise in communication scores starting at approximately six months. The two groups 
already show differences early in the study because most trainings began at the 14-17 day mark (or even 
earlier) after initiation of ART and any early RIAS and global affect measures included in at the zero time point 
(up to one month) are already reflecting the effects of training.  
 
Because the full training intervention was completed in an average of four months, it is clear from these graphs 
that the greatest difference in groups occurs around the six month time point. This is consistent with the 
findings at this time point that are shown in Table 4. The exception is doctor global positive affect, which shows 
only a slight difference at six months and is indeed weakly statistically significant (Figure 7).  
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                                    Figure 4: Patient positive effect means at key time points 
 
                                      Figure 5: Doctor information gathering means at key time points 
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                                        Figure 6: Doctor facilitation and patient activation means at key time points 
 
                                       Figure 7: Doctor global positive affect means at key time points 
            
 
N, Intervention
N, Control
271
267
135
121
147
127
213
180
46
37
People, Intervention
People, Control
187
184
129
111
128
110
160
129
40
35
0
2
4
6
8
1
0
1
2
1
4
1
6
F
a
c
ili
ta
ti
o
n
 a
n
d
 A
c
ti
v
a
ti
o
n
0 1 3 6 9
Months Standardized Time
Intervention
Control
N, Intervention
N, Control
256
251
137
117
140
123
207
162
24
28
People, Intervention
People, Control
175
171
129
109
122
106
155
118
23
27
0
2
4
6
8
1
0
1
2
1
4
1
6
D
o
c
to
r 
G
lo
b
a
l 
P
o
s
it
iv
e
 A
ff
e
c
t
0 1 3 6 9
Months standardized time
Intervention
Control
Final Report of Patient Education and Empowerment PHE 
20 | 
 Twelve Month Clinical Outcomes   
A secondary objective of the study was to examine clinical outcomes of intervention and control patients to 
determine if the training had any effect on health outcomes. These outcomes (ART adherence, BMI, weight, 
CD4 count, and incidence of OIs and ART treatment interruptions) were not found to be statistically significantly 
different between the two treatment arms, either at six months or 12 (or more) months after study start (Table 
6). Of note, however, this objective of the study was hampered by implementation of the study in a dynamic 
non-research environment; this affected the number of participants who were able to be followed for a full 12 
months or longer and greatly reduced the sample size at the 12 month time point. Also, the majority of ART 
patients only visit the clinic every three-six months after one year of ART, limiting the possibility that study 
patients would be seen at the clinic at 12 months or later. Finally, data abstracted from patient charts at the 
four ART clinics proved to be unreliable. Some clinics do not conduct pill counts, for example, and adherence 
data (when available) had to be indirectly measured by whether pills were picked up or not or by the mean 
number of days between pill pickups (only in the case of Katutura Health Centre, where national data were 
available). The ART clinics also do not routinely run CD4 counts, especially after the first two-three months that 
a patient is on ART and documentation of OIs and ART interruptions is also unreliable (at six months only 42 
CD4 counts were available). Clinics do not collect patient height so if study staff did not collect patient height 
it was impossible to calculate BMI. It is possible, though, given the positive effect of the training at six months 
that clinical outcomes could have been impacted by the intervention and a larger sample size and more reliable 
measures may have been able to detect this impact.  
 
      Table 6: Clinical outcomes at 6 and 12 months by study arm 
 
Outcome measure 
6 months 12 months 
Group 1 
(intervention) 
Group 2  
(control) 
 
P-value Group 1 
(intervention) 
Group 2  
(control**) 
 
P-value 
Adherence – pill count 
(Mean and SD*)  
86.3 (33.5) 
N=322 
90.2 (30.7) 
N=385 
0.10 78.1 (44.4) 
N=9 
75.3 (57.2) 
N=7 
0.91 
Adherence – pills picked up 
on required date (y/n) 
253 (89%)  
N=284 
253 (92%)  
N=274 
0.40 52 (95%)  
N=55 
40 (91%) 
N=44 
0.48 
Adherence – mean number 
of days between pill pickups 
and SD 
43.6 (37.6) 
N=606 
42.1 (39.8) 
N=659 
0.48 73.4 (55.6) 
N=64 
86.9 (10.4) 
N=50 
0.27 
BMI  22.3 (3.6) 
N=271 
22.1 (3.5) 
N=246 
0.68 22.5 (3.1) 
N=54 
22.2 (4.1) 
N=37 
0.70 
Weight (Mean and SD)  60.4 (11.5) 
N=412 
60.3 (10.5) 
N=385 
0.90 59.3 (10.0) 
N=60 
60.1 (11.7) 
N=38 
0.48 
CD4 Count  (Mean and SD) 400.9 (193.4) 
N=20 
463.8 (197.9) 
N=22 
0.30 447 (247) 
N=6 
521 (214) 
N=10 
0.54 
Opportunistic Infections 18 (3%) 
N=520 
22 (4%)  
N=537 
 
   0.56 
1 (1%) 
N=96 
0 (0%)  
N=69 
0.39 
ART Treatment Interruptions 6 (1%) 
N=501 
3 (.6%)  
N=521 
 
0.89 
0 (0%) 0 (0%)  --- 
      *SD=Standard Deviation  
      **=Since the control group was trained at six months at 12 months they are technically no longer controls  
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DISCUSSION 
This study has shown a positive impact of the patient education and empowerment curriculum intervention on 
patient-provider interactions. This is strongly supported by the statistically significant findings in five of the 13 
RIAS and global affect outcomes measured at the six month time point and in the positive direction of the majority 
of the 13 outcome means in the direction of the intervention group (Table 4).  
 
The training intervention also clearly impacted the providers themselves; doctors in the study gathered more 
information from trained patients, facilitated and activated patients and even showed more positive emotional 
affect during consultations. As an example of the types of interactions that combine as ‘facilitation and activation 
of patients’ these are times during a medical consultation when a doctor asks for a patients’ opinion, asks for 
permission (to examine a patient, for example), asks for reassurance, or paraphrases and checks for 
understanding from the patient. Although the study indicated a boost in these types of interactions for the 
patients and doctors, it is disheartening that during ART follow up these positive interactions wane over time 
(Figures 3-7). This may reflect the energy and effort that providers put into consultations with early ART patients 
that is not sustained  
 
In addition to utterance by utterance categorization, coders were asked to rate the affect or emotional context 
of the dialogue. These ratings were based on overall affective impressions of the speakers on such dimensions as 
dominance, assertiveness, friendliness, warmth, attentiveness and respectfulness. It is not clear why so few global 
affect categories had statistically significantly different effect sizes, as many of the RIAS categories did. It may be 
that coders were unfamiliar with either the format of the global affect scales or the definitions of the dimensions 
themselves (e.g., empathy or assertiveness) or these scales are too culturally-specific to Western health care 
systems and would need to be adapted more for use in Namibia or elsewhere. For RIAS coding, on the other 
hand, culturally-specific utterances during a consultation were discussed within the team and categorized 
according to a consensus of the study team.  
 
It is possible that some cross group contamination occurred between the two groups. Patients in Group 1 (the 
intervention group) could have had friends or family in Group 2 (the delayed intervention group). Also, many 
ART clinics in Namibia have a designated “new patient initiation” day once a week where all ART eligible 
patients will come to start treatment. These new patients also share similar (sometimes identical) follow up 
schedules. As these “new patients” included both intervention and control patients, there is the possibility that 
during follow up visits the intervention patients coached control patients in how to be empowered during their 
consultations. We tried to reduce this possible contamination by reminding patients that their study group and 
the content of the trainings were confidential.  
There is also the possibility of contamination of patients in the control group due to inadvertent “coaching” by 
health care providers before the patients in that group were trained. This possibility was reduced by blinding 
providers to group identification as much as possible by holding trainings out of the health care provider’s view 
and asking patients in the study to not discuss their treatment assignment with anyone they came into contact 
with at the facility. However, the study team observed that most providers were too busy to discern the study 
group of the patient and even if they did have some interest in this it waned as the study proceeded.  
Further bias could have been introduced by the coding of RIAS by the site coordinators, who were 
knowledgeable of the group assignment for each participant. This bias was mitigated by keeping the participant 
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log and training log locked away in a cabinet, especially during coding work. Still, it is possible the coder 
sometimes remembered the group assignment and this influenced coders’ work.  
The study was based in four purposively selected healthcare facilities and not a randomized sample. This 
decision was made to increase feasibility of the intervention evaluation within the budget, time and local 
implementation constraints. As a result, it does not allow the results to be generalized to the wider population 
of ART patients in the country. However, given that the study was randomized and controlled, and that site 
was adjusted for in the analyses, the results are very important to consider in terms of the feasibility and 
potential applicability for other facilities in Namibia.  
Finally, there is surely impact from missing data in the study – from either patient loss to follow up or by study 
team members’ ‘missing’ a patient’s follow up visit in the clinic, and thus missing an audio-taping of a 
consultation. The substantial loss to follow-up in this study may have led to either overestimates or 
underestimates of treatment effects. For this reason we analysed missing data further. We found it was more 
likely that control group audio-files were missed compared to intervention group audio-files (51.6% of control 
group audio-files were collected at six months compared to 60.0% in the intervention group, p=0.06), with the 
implication that data were not missing completely at random. It is possible that intervention patients were 
most likely to be recognized by the study coordinators when they arrived at the clinic and thus it was more 
likely that their audio-tapes were collected, introducing unconscious bias. Also, participants attended clinic 
visits at a high rate during the time period (approximately 88% of both groups came to clinic during the time 
period) so both groups of patients were equally available for the collection of the audio-tapes. The reduced 
power due to missing data made it more difficult to detect differences between the two study groups.  
As indicated earlier, study implementation challenges and the use of abstracted patient chart data hampered 
the study teams’ ability to determine the training intervention impact on clinical outcomes. The reliability of 
abstracted data should be considered in future evaluation studies in Namibia.  
In conclusion, ART is a lifelong therapy whose effectiveness depends on adherence to care and treatment. 
Patients need to feel that their role in care and treatment matters and this is partly dependent on the quality 
of their relationship with their provider. Given the immensity of HIV treatment campaigns in sub-Saharan Africa 
and elsewhere, more studies are needed to explore how patient-provider communication influences HIV care 
and treatment. In Namibia ART clinics should consider the positive impact on patient care and health outcomes 
that is possible from more targeted and in-depth patient education and empowerment.  
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